View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, April 2 (HealthDay News) -- Long-term use of estrogen hormone therapy (estrogen only [ET] or estrogen plus progesterone [E+P]) is associated with a higher risk for breast cancer, according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 31 to April 4 in Chicago.
Wendy Y. Chen, M.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues analyzed data for postmenopausal women from the Nurses' Health Study, collected from 1980 through 2008 for those aged 30 to 55 years old in 1976.
During 1.57 million person-years of follow-up, the researchers found that breast cancer risk increased with duration of current E+P use without evidence for a plateau (relative risk [RR], 1.88 for 10 to 14.9 years; RR, 2.35 for 15 to 19.9 years). Long-term current ET use also correlated with increased risk (RR, 1.22 for 10 to 14.9 years; RR, 1.43 for 15 to 19.9 years). When the population was restricted to the same entry criteria as the Women's Health Initiative trial there was still an increased risk for long-term current users (RR, 1.30 for 15 to 19.9 years). There was no increase in the risk of fatal breast cancer with either E+P or ET use (RR, 1.05 [95 percent confidence interval (CI), 0.67 to 1.68] and 1.08 [95 percent CI, 0.80 to 1.46], respectively, for 10 to 19.9 years of current use).
"Even though we saw an increased risk in developing breast cancer, we did not see an increased risk for dying from breast cancer," Chen said in a statement.
Abstract No. LB-60
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top